{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:02:12Z","timestamp":1773792132385,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,3,29]],"date-time":"2011-03-29T00:00:00Z","timestamp":1301356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11255-011-9941-x","type":"journal-article","created":{"date-parts":[[2011,3,28]],"date-time":"2011-03-28T01:11:33Z","timestamp":1301274693000},"page":"1047-1057","source":"Crossref","is-referenced-by-count":31,"title":["T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy"],"prefix":"10.1007","volume":"43","author":[{"given":"E.","family":"De Berardinis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. M.","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Giovannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,3,29]]},"reference":[{"key":"9941_CR1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/00000478-198709000-00002","volume":"11","author":"JY Ro","year":"1987","unstructured":"Ro JY, Ayala AG, el-Naggar A (1987) Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol 11:668\u2013673","journal-title":"Am J Surg Pathol"},{"key":"9941_CR2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BWB Rhijn van","year":"2009","unstructured":"van Rhijn BWB, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430\u2013442","journal-title":"Eur Urol"},{"key":"9941_CR3","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/01.ju.0000132129.87598.3b","volume":"172","author":"GN Thalmann","year":"2004","unstructured":"Thalmann GN, Markwalder R, Studer UE et al (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172:70\u201375","journal-title":"J Urol"},{"key":"9941_CR4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA et al (2006) Predicting recurrence, progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials. Eur Urol 49:466\u2013477","journal-title":"Eur Urol"},{"issue":"4","key":"9941_CR5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.juro.2006.11.090","volume":"177","author":"GV Raj","year":"2007","unstructured":"Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, Dalbagni G (2007) Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 177(4):1283\u20131286","journal-title":"J Urol"},{"key":"9941_CR6","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Meijden AP, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964\u20131970","journal-title":"J Urol"},{"key":"9941_CR7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1464-410X.2003.04655.x","volume":"93","author":"MD Shelley","year":"2004","unstructured":"Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD (2004) Intravesical bacillus Calmette-Gu\u00e9rin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 93:485\u2013490","journal-title":"BJU Int"},{"issue":"2","key":"9941_CR8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2003.09.013","volume":"45","author":"JA Witjes","year":"2004","unstructured":"Witjes JA (2004) Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45(2):142\u2013146","journal-title":"Eur Urol"},{"key":"9941_CR9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"9941_CR10","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.juro.2008.11.112","volume":"181","author":"BG Volkmer","year":"2009","unstructured":"Volkmer BG, Kuefer R, Bartsch C, Gust K, Hautmann RE (2009) Oncological followup after radical cystectomy for bladder cancer-is there any benefit? J Urol 181:1587\u20131593","journal-title":"J Urol"},{"key":"9941_CR11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2009.10.015","volume":"57","author":"M Babjuk","year":"2010","unstructured":"Babjuk M (2010) What is the optimal treatment strategy fo T1 bladder tumors? Eur Urol 57:32\u201334","journal-title":"Eur Urol"},{"key":"9941_CR12","unstructured":"Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou J, Roupret M (2010) European Association of Urology Guidelines"},{"key":"9941_CR13","doi-asserted-by":"crossref","unstructured":"Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M (2000) Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 4:CD001986","DOI":"10.1002\/14651858.CD001986"},{"key":"9941_CR14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A Bohle","year":"2003","unstructured":"Bohle A, Jocham D, Bock PR (2003) Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90\u201395","journal-title":"J Urol"},{"key":"9941_CR15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-5347(01)65853-1","volume":"156","author":"C Lundholm","year":"1996","unstructured":"Lundholm C, Norl\u00e9n BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T et al (1996) A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 156:372","journal-title":"J Urol"},{"issue":"2","key":"9941_CR16","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.ju.0000150425.09317.67","volume":"173","author":"TM Reijke de","year":"2005","unstructured":"de Reijke TM, Kurth KH, Sylvester RJ et al (2005) Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). J Urol 173(2):405\u2013409","journal-title":"J Urol"},{"key":"9941_CR17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","volume":"63","author":"A Bohle","year":"2004","unstructured":"Bohle A, Bock PR (2004) Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63:682\u2013686","journal-title":"Urology"},{"key":"9941_CR18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein DA, Crissman JD et al (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163:1124\u20131129","journal-title":"J Urol"},{"issue":"4","key":"9941_CR19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"AP Meijden van Der","year":"2003","unstructured":"van Der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44(4):429\u2013434","journal-title":"Eur Urol"},{"key":"9941_CR20","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2009.08.024","volume":"57","author":"GS Kulkarni","year":"2010","unstructured":"Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat A, Zlotta A (2010) An update critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previosly T1G3) bladder cancer. Eur Urol 57:60\u201370","journal-title":"Eur Urol"},{"key":"9941_CR21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0090-4295(02)01920-9","volume":"60","author":"G Dalbagni","year":"2002","unstructured":"Dalbagni G, Herr HW, Reuter VE (2002) Impact of second transurethral resection on the staging of T1 bladder cancer. Urology 60:822\u2013824","journal-title":"Urology"},{"key":"9941_CR22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/01.ju.0000072422.69286.0e","volume":"170","author":"JP Stein","year":"2003","unstructured":"Stein JP, Cai J, Groshen S, Skinner DG (2003) Risk factors for patients with pelvic lymph node metastses following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J Urol 170:35\u201341","journal-title":"J Urol"},{"key":"9941_CR23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","volume":"19","author":"JP Stein","year":"2001","unstructured":"Stein JP, Lieskovsky G, Cote R, Groshen S et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 19:666\u2013675","journal-title":"J Clin Oncol"},{"key":"9941_CR24","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","volume":"4","author":"GS Kulkarni","year":"2007","unstructured":"Kulkarni GS, Finelli A, Fleshner NE, Jewett MA, Lopushinsky SR, Alibhai SM (2007) Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 4:e284","journal-title":"PLoS Med"},{"issue":"3","key":"9941_CR25","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00345-009-0402-4","volume":"27","author":"RE Hautmann","year":"2009","unstructured":"Hautmann RE, Volkmer BG, Gust K (2009) Quantification of the survival benefit of early versus deferred cystectomy in high-risk non-muscle invasive bladder cancer (T1G3). World J Urol 27(3):347\u2013351","journal-title":"World J Urol"},{"issue":"2","key":"9941_CR26","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1464-410X.2008.08342.x","volume":"104","author":"P Gazzaniga","year":"2009","unstructured":"Gazzaniga P, Gradilone A, De Berardinis E, Sciarra A et al (2009) A chemosensitivity test to individualize intravesical treatment for non-muscle invasive bladder cancer. BJU Int 104(2):184\u2013188","journal-title":"BJU Int"},{"key":"9941_CR27","doi-asserted-by":"crossref","unstructured":"Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M et al. (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31(4):277\u2013285","DOI":"10.1007\/s13277-010-0033-9"},{"key":"9941_CR28","doi-asserted-by":"crossref","unstructured":"Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E et al. (2010) Prognostic significance of surviving-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int 106(5):710\u2013715","DOI":"10.1111\/j.1464-410X.2009.09130.x"},{"key":"9941_CR29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2003.11.027","volume":"45","author":"B Gattegno","year":"2004","unstructured":"Gattegno B (2004) T1G3 bladder cancer: conservative management or cystectomy? Eur Urol 45:399\u2013400","journal-title":"Eur Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-011-9941-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-011-9941-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-011-9941-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T13:13:05Z","timestamp":1560085985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-011-9941-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,29]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9941"],"URL":"https:\/\/doi.org\/10.1007\/s11255-011-9941-x","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,29]]}}}